Complimentary access to the JTO and a 25% discount on the publication fees for the newest open-access IASLC journal, JTO CRR. Both JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO is now among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology.
Free access to the JTO and a 25% discount to the open-access fees for the newest IASLC journal, JTO CRR. Both JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO is now among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology.
JTO by the Numbers
11
out of 244 in 2019 Oncology Journals
3
out of 64 in 2019 Respiratory Journals
13.357
Impact Factor (up from 12.460 in 2018)
1,704%
increase in 6 years full-text article downloads
Recent journal articles
Serial plasma cell-free circulating tumor DNA tests identify genomic alterations for early prediction of osimertinib treatment outcome in EGFR T790M-positive non-small cell lung cancer
Brief report “Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis”
Correlating ROS1 Protein Expression with ROS1 Fusions, Amplifications, and Mutations
Associations of aspirin, statins, and metformin with lung cancer risk and related mortality: time-dependent analysis of population-based nationally representative data
Brief report: Two Year Follow-up of a Randomized Controlled Study of Integrated Smoking Cessation in a Lung Cancer Screening Program
Successful treatment of EGFR mutant Synchronous Small cell carcinoma and Adenocarcinoma Lung with osimertinib
Whole Exome Profiling of NSCLC Among African Americans
Combination of atezolizumab, bevacizumab and chemotherapy (IMpower 150) in non-small cell lung cancer patient with leptomeningeal metastases
Discover the JTO
JTO.org offers numerous ways to stay abreast of novel research and information vital to your daily oncology practice. Join the JTO reader community to:
More than 80 international experts compose the JTO Editorial Board, allowing for a quick turn-around time of 5.4 days to initial decision, and an average of 7 days for revisions, a fast track category, publish on acceptance (within 5 days), and promotion of select articles via social media and press releases.
JTO emphasizes a multidisciplinary approach and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. Authors can take advantage of Elsevier's Researcher Academy, Navigate your research journey with Researcher Academy—free e-learning modules on navigating your career developed by global experts.
JTO reviewers are given the privilege of getting the first look at novel research, phase III data, and potentially practice-changing concepts. Email your CV to [email protected].
Discover the JTO CRR
Providing a more clinical focus, the JTO CRR contains phase I thoracic oncology clinical trials and single-arm phase II trials, as well as case reports, subset analyses of a published trials, database analyses, retrospective trials, and large single-institution series.
In addition to the content discussed previously, JTO CRR also accepts region-specific clinical trials, subspecialty thoracic oncology studies, and select high-quality meeting reports.
To become a JTO CRR Reviewer email your CV to [email protected].
Related Content
![AlexAdjei[1]](/sites/default/files/styles/d08_standard/public/migrated/AlexAdjei1.jpg?h=12df1d24&itok=pJJYtpHH "AlexAdjei[1]")